Connect with us


Mix-match COVID-19 booster shot offers better protection – Study



GIVING a different vaccine as the third dose than was received for the first two shots leads to better performance compared to using the booster of same preventive.

  According to a study published in The Lancet Global Health Journal, the research assessed the effectiveness of CoronaVac, Pfizer and AstraZeneca vaccine boosters in individuals who had a primary two-dose immunisation schedule with CoronaVac, compared with no vaccination.

  The researchers from the Universidad del Desarrollo, Pontificia Universidad Catolica de Chile, and colleagues from the Chilean Ministry of Health looked at Chile’s national immunisation programme, where two-dose Coronavac schedule was by far the most widely used. Individuals administered vaccines from February 2, 2021, to the pre-specified trial end date of November 10, 2021, were evaluated while they estimated the vaccine effectiveness of booster doses against laboratory-confirmed symptomatic COVID-19 cases and COVID-19 outcomes — hospitalisation, admission to the intensive care unit (ICU) and death.

  A total of 11,174,257 individuals were eligible for this study, among who 4,127,546 completed a primary immunisation schedule (two doses) with CoronaVac and received a booster dose during the study period.

  As many as 1,921,340 (46 5 per cent) participants received an AstraZeneca booster, 2,019,260 (48 9 per cent) received a Pfizer booster, and 1,86,946 (4 5 per cent) received a CoronaVac third shot.

  It will be recalled that CoronaVac is an inactivated SARS-CoV-2 vaccine which accounts for about half the COVID-19 vaccine doses delivered globally.

the researchers said. Similarly, a phase 1-2 study in the US with mRNA boosters found that heterologous boosters where on average more immunogenic than homologous boosters, they added.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published.


Top Posts